New organoid model of neuroendocrine tumours developed
NETs require epidermal growth factor to grow, meaning that inhibiting EGF receptors could treat these types of tumours.
List view / Grid view
NETs require epidermal growth factor to grow, meaning that inhibiting EGF receptors could treat these types of tumours.
Using saturation genome editing, researchers have created a map of disease-causing mutations for neurodevelopmental disorders and cancer.
Increasing microRNA-22 overexpression in a gene therapy approach treated HCC in mice, offering promise for its prevention and treatment.
Discovery about the NPM1c variant could lead to new drugs targeting the cell growth of acute myeloid leukaemia.
Carboxylic nanodiamonds could be a therapeutic agent for cancer, as melanoma cells treated with them showed little to no metastasis.
An advanced computational model enables scientists to study how cancer cells navigate through blood vessels.
New findings about how RBM10 inhibits lung cancer growth offers potential for an anti-cancer drug and more personalised treatment.
Studying pancreatic ductal adenocarcinoma tumours, researchers discovered 25 antibodies that responded to antigens.
Combining cancerous and non-cancerous cell patterns, the AI model evaluates breast cancer outcomes better than expert pathologists.
27 November 2023 | By
Welcome to Drug Target Review’s Cancer Research Hub. Here, we provide the latest insights and updates in the field of cancer research. Explore recent advancements in pharmaceuticals, drug discovery and potential breakthroughs in therapy. We conduct interviews with experts in the field, as well as in-depth features.